Recent News and Articles on the Keywords: report + 0.23 + center  Related to the article below (Last Update: 8/7/2008)

Odyssey HealthCare Reports Second Quarter 2008 Results MarketWatch - Aug 4, 2008 We are currently on schedule to complete the transition of the VistaCare corporate functions to our Dallas Support Center by year end and to have all the ...ODSY Jonathan Atkin ? RBC Capital Markets Seeking Alpha, NY - Internap?s total liabilities to equity ratio was 0.23:1 when compared to our stockholders? equity of $348 million. Our balance sheet includes approximately ...INAP Pinnacle Entertainment Reports Second Quarter 2008 Results CNNMoney.com (press release) - The Company completed the refurbishment of the suites at HoteLumiere; opened a new pedestrian tunnel that connects Lumiere Place to the America?s Center ...PNK The St. Joe Company Reports Second Quarter 2008 Financial Results StreetInsider.com (subscription), MI - Aug 5, 2008 The St. Joe Company (NYSE: JOE) today announced a Net Loss for the second quarter 2008 of $(20.8) million, or $(0.23) per share, compared to Net Income of ...JOE AEGON Reports Solid Business Performance and Strong Capital Position MarketWatch - Value of new business is not based on IFRS, which are used to report AEGON's quarterly statements and should not be viewed as a substitute for IFRS ...AEG - AEB - AEF Cray Inc. Reports Second Quarter 2008 Financial Results MarketWatch - Jul 31, 2008 In July, Cray announced a major achievement on the part of the Pittsburgh Supercomputing Center where, on a Cray XT3 system, researchers incorporated ...CRAY ID Systems, Inc. Reports Second Quarter Financial Results MarketWatch - Jul 31, 2008 Xerox Corporation became the first ID Systems customer to order the PowerKeyPLUS(tm) system, to be deployed on a fleet of forklifts at a distribution center ...IDSY Middleburg Financial Corporation Announces 2008 Second Quarter ... CNNMoney.com (press release) - Aug 5, 2008 "While we are certainly disappointed with this quarter?s earnings report, we are confident that our aggressive actions in dealing with our problem credits ...MBRG Dayton Superior Reports Record Second Quarter Net Income StreetInsider.com (subscription), MI - Jul 30, 2008 Our marketing and sales disciplines, manufacturing productivity, distribution center controls, and new product sales were all key to our improved ...DSUP WELT ONLINE Prosperity Bancshares, Inc.(R) Reports Second Quarter Earnings Earthtimes (press release), UK - Jul 23, 2008 The Bank of Navasota operated one (1) banking office in Navasota , Grimes County, Texas , which became a full service banking center of Prosperity Bank. ... WaMu Reports Significant Build-Up of Reserves Contributing to ... Trading Markets (press release) all 1,034 news articles »  WM - PRSP - KIDS

Determining a Better ADHD Drug Proves Elusive

Just after the Centers for Disease Control reported that 2.5 million children and 1.5 million adults are currently taking myriad medications for attention deficit disorder (ADHD), a drug first approved for narcolepsy could be the latest addition.

While one might question the connection between treating a sleep disorder and an attention problem, this newest finding highlights the confusion over how to determine which of the many options is the best choice for treating ADHD.

"Few studies pit one stimulant against another in a head-to-head comparison." said Dr. Marian McDonagh from the Oregon Evidence-based Practice Center at the Oregon Health and Science University.

The Newest in a List of Drugs for ADHD
This problem can be seen with the most recent study confirming the positive effects Provigil (modafinil) has on kids with ADHD. Provigil, is approved as a "wake-promoting agent" for those sluggish from a lack of sleep, specifically for shift workers. Logically, it seems to follow that the same drug would also help those who have trouble staying attentive during the day.

After early studies showed that Provigil helped adult patients with ADHD, Cephalon, the company that manufactures the drug, created a pediatric version to be tested for widespread use.

During a nine-week-long study, which was presented at the 2005 Annual Meeting of the American Psychiatric Association (APA), the pediatric version of Provigil was shown to improve children’s scores on a standardized test.

"This study not only shows that this medication is effective and rapid in onset for the treatment of pediatric ADHD." said lead researcher Dr. Joseph Biederman, chief of pediatric neuropsychopharmachology at Massachusetts General Hospital, "It also gives the clear signal that we have a medication that can be used…to treat ADHD in children who cannot tolerate amphetamines."

Even if Provigil did have a positive effect, in the study it was only compared to a placebo, not to Ritalin nor any other drug for that matter.

"Short-term trials do not provide clear evidence that any one stimulant is any more tolerable than another." said McDonagh.

Comparing the Options
With almost 20 drugs being used for the treatment of ADHD, ranging from stimulants to antidepressants, things can get confusing. Most doctors simply prescribe the popular stimulants Ritalin, Concerta or Adderall. But if the patient doesn’t respond to these drugs or if the side effects are intolerable, as is the case 60 to 80 percent of the time, an alternative method needs to be tried.

The problem is finding an option that seems to work best.

Of the 2,287 papers that McDonagh reviewed for her analysis, published in September 2005 by the Drug Effectiveness Review Project, the only drug ever used in comparison studies is Ritalin, the drug recommended by the American Academy of Pediatrics as a first-line against ADHD.

But even in those studies, the vast majority were short-term with limited numbers of mostly Caucasian participants, leaving almost none that looked at the long-term effectiveness, side effects or possible ethnic differences to show if one treatment truly worked better than another.

"The bottom line is that [choosing a drug for treatment] is trial and error." says Dr. John Santa, medical director of the Drug Effectiveness Review Project, a program dedicated to analyzing the data on various types of drugs to determine the safest and most helpful option.

Shaping the Future of ADHD Treatment
For people looking for good ADHD treatment, the key is, says Santa, finding a reputable doctor. Patients should also be sure to let the doctor know if cost is a problem, as some brand-name drugs can be quite pricey. "If money is an issue, there are some alternatives that are just as good." says Santa.

Santa and his colleagues were astounded by the gaping holes in the understanding of ADHD treatment and large number of studies that did not produce any new data. It seems that many more studies will be necessary to first determine the true pros and cons of the traditional mediations before even beginning to determine whether Provigil, or any new drug for ADHD, is truly better or worse than another.

"We are drowning in information, starved for knowledge." he says.

Looking towards the future, the biggest problem, according to Santa, is that the medical community doesn’t require head-to-head trials before a drug goes to market.

"We need to look within ourselves because we don’t require or reward comparison studies." said Santa.